Atara Biotherapeutics Inc

NASDAQ: ATRA
$7.69
+$0.49 (+6.8%)
Closing Price on October 4, 2024

ATRA Stock Chart and Intraday Price

ATRA Stock Data

Asset Type Common Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Address 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO, CA, US
Fiscal Year End December
Latest Quarter 2023-12-31
Market Cap 81.66M USD
Shares Outstanding 101,922,000
Atara Biotherapeutics, Inc., a commercially available T-cell immunotherapy company, develops treatments for cancer patients, autoimmune and viral diseases in the United States. The company is headquartered in South San Francisco, California.

ATRA Articles

Beyond Mesothelioma, Multiple Sclerosis Could Help Atara's Stock Soar Exponentially
On Tuesday, Canaccord Genuity reiterated its rating on Atara Biotherapeutics and raised its wildly bullish target price even higher.
Jon C. Ogg
Published:

Should Atara Bio's Stock Volatility Consider Any Valuation at All on Multiple Sclerosis?
Atara Biotherapeutics finds itself caught between a rock and a hard place after Friday's drug study news concerning its treatment for multiple sclerosis.
Jon C. Ogg
Published: